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QuetiapineWe previously reported that treatment with 160 mg/d of lurasidone improved cognitive performance in a man-
ner superior to placebo, quetiapine XR 600mg/d, and lurasidone 80mg/d, based on a 6-week randomized trial of
patients with an acute exacerbation of schizophrenia. The objective of this post-hoc analysis was to explore the
cognitive and functional performance of patients whose ﬁnal doses of lurasidone were 40/80 mg/d, 120 mg/d,
and 160 mg/d compared to quetiapine XR 200-800 mg/d (QXR) during a 6-month, double-blind continuation
study that followed a short-term trial. Subjects who received ﬁnal doses of lurasidone 120 mg/d (n = 77) and
160 mg/d (n = 49) showed signiﬁcantly greater improvement in overall cognitive performance compared to
QXR (n = 85) at week 32 (month 6 of the extension study), while those on last doses of 40/80 mg/d (n = 25)
showed a trend towards signiﬁcance at week 32. Mean changes in neurocognitive composite z-score from pre-
treatment baselinewere signiﬁcant for the 3 lurasidone ﬁnal dose groups at bothweeks 19 and 32,with compos-
ite change scores of z = 1.53, z = 1.43, and z = 1.34 for the lurasidone 40/80 mg/d, 120 mg/d, and 160 mg/d,
respectively, at week 32. In contrast, the composite change score was not statistically signiﬁcant in the overall
quetiapine group (z=0.46),with none of the individual quetiapine doses showing any signiﬁcant improvement.
Functional capacity scores improved in all treatment groups. Our ﬁndings indicate improved cognitive perfor-
mance in patients treated with each of the ﬂexible doses of lurasidone 40–160 mg/d, compared to quetiapine
XR 200–800 mg/d. All doses of lurasidone were superior to all doses of quetiapine for cognitive performance.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The focus of mental healthcare has increasingly shifted from the
“disease” model of symptom amelioration and relapse prevention to
the “rehabilitation” model of functional recovery, patient well-being,
and restoration of real-world functioning (Bowie et al., 2006; Leifker
et al., 2011). Cognitive deﬁcits are core features of schizophrenia
(Harvey and Keefe, 2001; Nuechterlein et al., 2012) and represent a
key predictor of poor functional outcomes (Leifker et al., 2011; Harvey
et al., 2013). Despite several large-scale trials conducted to investigate
novel treatment options, there are, however, no pharmacological inter-
ventions approved to date to treat this component of the disorder
(Keefe et al., 2013). Previous reports have suggested remission in nega-
tive symptoms and long-term functional beneﬁts can be attained inor of Psychiatry and Behavioral
e, 1120 NW 14th Street, Suite
x: +1 305 243 1619.
. This is an open access article underpatients who continued treatment with atypical antipsychotics in a
double-blind, follow-up study of up to 196 weeks (Potkin et al., 2009;
Stahl et al., 2010).
Lurasidone is a novel benzisothiazol derivative with potent binding
afﬁnity for D2, 5-HT2A and 5HT7 receptors (antagonist), moderate afﬁn-
ity for 5HT1A (partial agonist) and α2C receptors (antagonist), and no
appreciable afﬁnity for H1 and M1 receptors (Ishibashi et al., 2010).
The procognitive effect of lurasidone was supported in preclinical stud-
ies (Ishiyama et al., 2007; Enomoto et al., 2008; Horisawa et al., 2011), as
well as by a 3-week, double-blind, active-controlled study of lurasidone
and ziprasidone (Harvey et al., 2011). In a randomized, double-blind, 6-
week, placebo- and active-controlled acute study, lurasidone 160 mg/d
demonstrated superiority to both placebo (Cohen's d = 0.37) and
quetiapine 600 mg/d (d = 0.41) on a neurocognitive composite score,
while lurasidone 80 mg/d, quetiapine XR 600 mg/d, and placebo did
not signiﬁcantly differ (Harvey et al., 2013).
Determining the therapeutic dose range and dose–response rela-
tionships is essential to pharmacotherapeutic research and treatment
interventions (Davis and Chen, 2004). This may be especially critical
for optimizing treatment strategies to maximize the beneﬁcial effectsthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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et al., 2013). The objective of this post-hoc analysis was to explore dose
effects of lurasidone on cognitive performance in schizophrenia in a 6-
month, double-blind continuation study that followed a short-term
trial. Patients receiving 40, 80, 120, or 160 mg/d of lurasidone were
compared to patients receiving quetiapine XR at the end of the contin-
uation study. Each lurasidone dose was compared to the entire sample
of quetiapine XR patients; due to small sample sizes, individual
quetiapine XR doses were examined on an exploratory basis.
2. Methods
The analysis reported here is based on data from a previously report-
ed randomized, double-blind, 6-week, placebo- and active-controlled
acute study (Harvey et al., 2013; Loebel et al., 2013a), followed by a
double-blind continuation study that continued up to 1 year (Loebel
et al., 2013b); the design of these studies will therefore be only brieﬂy
summarized here. The study was approved by an institutional review
board at each investigational site and was conducted in accordance
with the International Conference on Harmonisation of Good Clinical
Practices guidelines, and with the ethical principles of the Declaration
of Helsinki. All patients signed an informed consent document
explaining study procedures and potential risks before study entry.
2.1. Subjects
Subjects with a primary diagnosis of schizophrenia, who had recent-
ly been hospitalized for an acute exacerbation of psychotic symptoms,
were randomly assigned to receive 6 weeks of double-blind treatment
with once-daily doses of lurasidone (80 mg or 160 mg), quetiapine XR
(600 mg), or placebo. Upon completion of the initial 6-week study, eli-
gible subjects were enrolled in the 1-year, double-blind continuation
study, where subjects continued treatment with either ﬂexible-dose
lurasidone 40–160 mg/d or quetiapine XR 200–800 mg/d. Cognitive
and functional capacity assessments were obtained at months 3 and 6
of the 1-year continuation study. For the purposes of this analysis,
lurasidone or quetiapine XR dose was deﬁned as the last dose received
by subjects during the initial 6 months of the continuation study.
Lurasidone doses assessed were 40/80 mg/d, 120 mg/d, and 160 mg/
d; quetiapine XR doses assessed were 200/400 mg/d, 600 mg/d, andFig. 1. Disposition of subjects. LUR80: lurasidone 80 mg/d800 mg/d. The 40 and 80 mg/d lurasidone doses and the 200 and
400mg/d quetiapine XR doses were combined due to the small number
of subjects using these doses during the continuation study. All study
medications were taken once daily, in the evening, with food.
Subjects who had been treated with placebo in the initial 6 week
study were switched in blinded fashion to ﬂexible dose lurasidone
treatment, but the present analyses focused primarily on those patients
receiving lurasidone during both the acute and continuation study
phases (LUR-to-LUR). Entry into the continuation study required sub-
jects to have completed all assessments on the ﬁnal week 6 visit of the
acute phase, and judged by the investigator as suitable for research-
oriented treatment in an outpatient setting.
2.2. Assessments
The CogState Computerized Cognitive Battery (Pietrzak et al., 2009)
was administered by trained examiners at pre-treatment baseline,
week 6 (end of the acute study) and weeks 19 (month 3 of the contin-
uation study) and 32 (month 6 of the continuation study). The primary
cognitive outcomemeasure was the composite Z-score, which was cal-
culated as an average of the 7 standardized Z-scores over the 7 task do-
mains. If three or more components were missing at a visit, the
composite score was set to missing (Pietrzak et al., 2009).
The University of California San Diego (UCSD) Performance-based
Skills Assessment-Brief version (UPSA-B; Mausbach et al., 2007) was
administered at the acute study baseline (randomization), week 6
(end of the acute study), and after 3 months (week 19) and 6 months
(week 32) of double-blind continuation study treatment. The UPSA-B
consists of two of the ﬁve original UPSA domains, ﬁnances and commu-
nication, and has been shown to be highly correlatedwith the long form
of the UPSA and to have substantial test–retest reliability. Each subscale
contributes 50 points so that total scores range from 0 to 100 points,
with higher scores reﬂecting better performance.
2.3. Statistical methods
The dose effect of lurasidone (based on the last dose received by pa-
tients in the continuation study phase) on cognitive functioning atweek
32 (month 6 of the continuation study) was evaluated using a mixed-
effects longitudinal data analysis (LDA) model (Fitzmaurice et al.,; LUR160: lurasidone 160 mg/d; QXR: quetiapine XR.
Fig. 2. Cognitive overall performance at week 32: Lurasidone last-dose groups (from lurasidone in acute phase) vs. quetiapine XR (from quetiapine in acute phase).
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acute phase (at week 0) as part of the repeated measures outcome var-
iable, with ﬁxed effects terms for visit, visit-by-treatment, and pooled
centers, as well as an unstructured covariancematrix for random effects
(Fitzmaurice et al., 2004). The primary treatment group comparison
was between patients continuing on ﬂexibly dosed lurasidone (LUR-
to-LUR) who received last lurasidone dose of 40/80 mg/d, 120 mg/d,
or 160 mg/d in the continuation study phase, and all patients in the
quetiapine XR group. No adjustment for multiple treatment compari-
sons and/or multiple outcomes was applied in this exploratory analysis.
4. Results
Fig. 1 depicts the disposition of subjects in the double-blind, 6-
month, continuation study. A total of 292 subjects completed the 6-
week acute phase and were enrolled in the double-blind continuation
study. The median last dose in the overall lurasidone group (LUR-to-
LUR, n= 151) was 120 mg/d at the month 6 end point. Of the 151 sub-
jects, 49 (32.5%), 77 (51.0%), and 25 (16.6%) received ﬁnal doses of
lurasidone160 mg/d, 120 mg/d, and 40-80 mg/d, respectively, at
month 6. The median last dose in the quetiapine XR group (QXR600-
to-QXR, n = 85) was 600 mg/d. At month 6, last doses of quetiapine
XR 800 mg/d were received by 28 patients (33%), 600 mg/d by 47 pa-
tients (55%), and 200–400 mg/d by 10 patients (12%).
Improvement in cognitive performance was signiﬁcantly greater in
patients receiving last doses of lurasidone120 mg/d (p = 0.02) and
160 mg/d (p= 0.05) in the LUR-to-LUR group, compared to the overall
quetiapine XR group (Fig. 2). Therewas a trend towards signiﬁcance for
the lowest lurasidone dose group (40/80mg/d) compared to the overall
quetiapine XR group (p = 0.06) (Fig. 2). The mean change in
neurocognitive composite z-score from acute phase baselinewas signif-
icant for the overall lurasidone group (LUR-to-LUR) at both weeks 19
and 32 (months 3 and 6 of the continuation study) (Table 1), with com-
posite change z-scores of 1.53 (p b 0.05), 1.43 (p b 0.05), and 1.34
(p b 0.05) at month 6 end point for the dose groups of lurasidone 40/
80 mg/d, 120 mg/d, and 160 mg/d, respectively. In contrast, the change
in neurocognitive composite z-score was not statistically signiﬁcant in
the overall quetiapine XR group (z = 0.46) (p N 0.05), with none ofthe individual quetiapine XR doses showing any signiﬁcant improve-
ment (mean change in z-score: 1.23 for 200/400 mg/d; 1.73 for
600 mg/d;−0.17 for 800 mg/d) from acute phase baseline.
Mean improvement in UPSA-B from acute baseline to week 32 was
signiﬁcant for all dose groups of lurasidone, ranging from 12.2 points
(SE 2.6) for the last dose of 40/80 mg/d to 9.2 (SE 2.0) for the 160 mg/
d group. These lurasidone dose groups were not signiﬁcantly different
from the overall quetiapine XR group at week 32 (12.1, SE 1.7).
Fig. 3 shows that patients receiving a last lurasidone dose of 40/
80 mg/d had signiﬁcantly better performance in visual learning (p =
0.03), working memory (p = 0.01), and social cognition (p = 0.01)
compared to the overall quetiapine XR group. Patients receiving a last
lurasidone dose of 120 mg/d had signiﬁcantly better performance in vi-
sual learning (p= 0.002), workingmemory (p= 0.03), and reasoning/
problem solving (p = 0.013) compared to the overall quetiapine XR
group. Patients receiving a last lurasidone dose of 160 mg/d had signif-
icantly better performance in speed of processing (p= 0.04) compared
to the overall quetiapine XR group. Superior performance at a trend
level of signiﬁcance (p = 0.06) was observed in social cognition for
the 120 mg/d lurasidone group, and in attention/vigilance for the 40/
80 mg/d and 160 mg/d lurasidone groups compared to the overall
quetiapine XR group.
Among patients who switched from placebo in the acute phase to
lurasidone in the continuation study (PBO-LUR, n = 56), those in the
highest dose group of lurasidone 160 mg/d (PBO-LUR160, n = 21)
showed signiﬁcantly (p b 0.05) greater improvement in the
neurocognitive composite z-score from acute baseline to month 6
(zchange=1.21, SE 0.57, p= 0.033), but not the lower dose groups. How-
ever, these other dose comparisons were likely underpowered because
of the small sample size.
5. Discussion
This post-hoc analysis extends previous ﬁndings regarding the effect
of lurasidone on neurocognitive performance by exploring the dose ef-
fect of lurasidone on reducing neurocognitive impairment, in patients
whose ﬁnal doses of lurasidone were 40/80 mg/d, 120 mg/d, or
160 mg/d (versus ﬁnal doses of quetiapine XR 200–400 mg/d,
Table 1
Least-squares mean change in cognitive composite score from acute baseline by last dose in the Continuation Study (mixed effects model, full analysis sample).
Visit Week 19 Week 32
Treatment
(last dose by week 32)
LUR-to-LUR40/80
n = 25
LUR-to-LUR120
n = 77
LUR-to-LUR160
n = 49
QXR600-QXR
n = 85
LUR-to-LUR40/80
n = 21
LUR-to-LUR120
n = 55
LUR-to-LUR160
n = 37
vs.
QXR600-QXR
n = 57
Z-Score change from
baseline 95% CI
1.05*
0.27, 1.83
0.97*
0.45, 1.49,
0.79*
0.20, 1.39
0.31
-0.24, 0.86
1.53*
0.55, 2.51
1.43*
0.84, 2.03
1.34*
0.64, 2.10
0.46
–0.19, 1.10
Treatment Difference (SE) t,
p-value (vs. QXR600-QXR)
t = 1.62
(p = 0.107)
t = 1.89
(p = 0.060)
t = 1.28
(p = 0.202)
t = 1.89
(p = 0.06)
t = 2.39
(p = 0.017)
t = 1.97
(p = 0.050)
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lurasidone (i.e., 40/80mg/d,120mg/d, or 160mg/d)were superior to all
doses of quetiapine (i.e., 200–400 mg/d, 600 mg/d, or 800 mg/d) for
cognitive performance in the continuation study, where the dose
groups of lurasidone and quetiapine XR were determined from the
last dose received in the continuation study. Among subjects who re-
ceived lurasidone in both acute and continuation study phases (LUR-
LUR, n = 151), all three dose groups of lurasidone 40/80 mg/
d,120 mg/d, or 160 mg/d were associated with signiﬁcantly improved
performance on the neurocognitive composite score from baseline to
weeks 19 (month 3 of the continuation study) and 32 (month 6 of the
continuation study). At month 6, the 120 mg/d and 160 mg/d groups
showed signiﬁcantly better cognitive performance compared to the
quetiapine XR 200–800 mg/d group (QXR600-QXR). The improvement
in functional capacity (as assessed by the UPSA-B) also continued
through week 32 for the three lurasidone dose groups, and the mean
change scores were not signiﬁcantly different compared to the
quetiapine XR group. Our previously published analysis of this study
showed the correlation between changes in cognitive and UPSA-B as-
sessments was signiﬁcant at week 32 (Harvey et al., 2013). We did
not repeat those analyses here because of low power for comparing cor-
relations across the different dose groups.
Cognitive deﬁcits are present at all stages of schizophrenia and are
related to functional outcomes (Nuechterlein et al., 2012). WeFig. 3. Cognitive performance for domains at week 32: Lurasidonconducted an exploratory analysis to evaluate dose effects of lurasidone
on neurocognitive performance and a range of cognitive domains
known to be disturbed in schizophrenia. Results suggested that
lurasidone 40–160 mg/d improved cognition more than quetiapine XR
200–800 mg/d across all cognitive domains (Fig. 3). Greater improve-
ment in the speed of processing domain was found in subjects who re-
ceived the highest last dose of lurasidone 160mg/d,while improvement
in visual learning,workingmemory, reasoning/problem solving, and so-
cial cognition were greater in subjects who received lower last doses of
lurasidone (40/80 mg/d or 120 mg/d). The beneﬁcial effects of
lurasidone (versus quetiapine) might be explained, in part, by the dif-
ferential receptor pharmacology of these agents. Speciﬁcally, quetiapine
is a strong antagonist at H1 receptors, which has been linked to daytime
sleepiness (Witek et al., 1995; Baldwin and Scott, 2009; Loebel et al.,
2013c). Given that quetiapine XR may be associated with higher levels
of daytime somnolence compared to lurasidone (Loebel et al., 2013c),
it is possible that this effect could mediate a worsening of cognitive
functioning associated with quetiapine XR.
It is of note that data for this analysis were drawn from the ﬁrst
placebo-controlled, acute study to date to ﬁnd the investigational drug
treatment superior to an active comparator, followed by a 6-month,
double-blind extension where cognitive performance was also
assessed.(Harvey et al., 2013). The study by Harvey et al. was designed
to address the methodological limitations of previous studies thate last dose groups vs. quetiapine XR (mixed effects model).
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ing cognitive performance in schizophrenia. Enhancements included
the use of placebo in the acute phase and an active control to examine
practice effects and bias due to regression-to-the-mean (Allison et al.,
2009), adherence to the consensus research design (Buchanan et al.,
2005), and a performance-based, co-primary measure of functional ca-
pacity (Mausbach et al, 2007). It also addressed the pseudospeciﬁcity is-
sues by adjustment for concurrent symptomatic improvement in PANSS
total and subscales (Harvey et al., 2013).
Limitations inherent in the original and current investigation should
also be mentioned. Treatment with the higher dose of lurasidone
160 mg/d demonstrated a superior cognitive enhancement effect over
placebo and quetiapine XR in the evaluable analysis sample (n = 267)
in the acute phase, while lurasidone 80 mg/d and quetiapine XR
600 mg/d did not differ. This may reﬂect the challenges to obtaining
valid computerized neurocognitive testing scores in acutely psychotic
patients in the initial 6-week acute study (with a mean PANSS baseline
score of 101.4, SD 11.12 in the non-evaluable sample) (Harvey et al.,
2013). The observed testing failure rate was, however, consistent with
those observed in previous studies using computerized assessments
(Harvey et al, 2004; Keefe et al., 2007). The full analysis sample was
used in this post-hoc analysis in the 6-month continuation study,
which showed a statistically signiﬁcant treatment difference in
neurocognitive performance at month 6 favoring the lurasidone group
versus the quetiapine XR group. Findings were derived for speciﬁc
lurasidone and quetiapine XR doses based on the last dose received in
the continuation study (up to 6 months); these results may differ
from those obtained had ﬁxed doses of study medication been used
throughout the continuation study period. However, improvement of
neurocognitive composite z-score was consistent at weeks 19 and 32,
suggesting a trend of continued increase in cognitive performance
over time. Findings from this analysis based on derived last dose of
lurasidone in the continuation study warrant future investigation. The
discrepancies in dose response compared to the 6-week study need to
be studied more closely, but the beneﬁts of lurasidone compared to
quetiapine XRover the 6-month continuation studywere all statistically
signiﬁcant, and change scores were too substantial to be attributed to
practice effects. Improvement in the UPSA-B was smaller than those
seen in the neurocognitive measures and a practice effect for this mea-
sure cannot be conclusively ruled out.
In summary, neurocognitive performance associated with all doses
of lurasidone (between 40 and 160 mg/d) was superior to quetiapine
XR 200–800 mg/d in this long-term, double-blind continuation study
that followed a short-term, placebo-controlled trial. Improvement in
functional capacity assessment appeared to be similar for both treat-
ment groups. Further study is needed to conﬁrm these ﬁndings, given
the post-hoc nature of this exploratory analysis.
Role of Funding Source
This studywas sponsored by Sunovion Pharmaceuticals Inc. The sponsorwas involved
in the study design and collection of data.
Contributors
All authors contributed to the design of the study. Drs. Harvey and Siu undertook the
statistical analysis. Drs. Harvey and Siu prepared the ﬁrst draft of the manuscript. All au-
thors contributed to and approved the ﬁnal manuscript.
Conﬂict of Interest
Dr. Harvey serves as a consultant/advisory boardmember for Boeheringer-Ingelheim,
Forum Pharma, Genentech, Lundbeck, Otsuka-America, Roche Pharma, Sanoﬁ, Sunovion,
and Takeda. Dr. Siu serves as a consultant for Pﬁzer Inc. and Sunovion Pharmaceuticals.
Dr. Ogasa is an employee of SumitomoDainippon Pharma Co., Ltd. Dr. Loebel is an employ-
ee of Sunovion Pharmaceuticals.
Acknowledgments
All individuals who contributed to this paper are listed as authors. No professional
medical writer was involved in any portion of the preparation of the manuscripts. Data
were collected by staff members who did not have input into the scientiﬁc direction of
this paper.References
Allison, D.B., Loebel, A.D., Lombardo, I., et al., 2009. Understanding the relationship be-
tween baseline BMI and subsequent weight change in antipsychotic trials: effect
modiﬁcation or regression to the mean? Psychiatry Res. 170, 172–176.
Baldwin, C.M., Scott, L.J., 2009. Quetiapine extended release: in schizophrenia. CNS Drugs
23, 261–269.
Bowie, C.R., Reichenberg, A., Patterson, T.L., et al., 2006. Determinants of real world func-
tional performance in schizophrenia: correlations with cognition, functional capacity,
and symptoms. Am. J. Psychiatry 163, 418–425.
Buchanan, R.W., Davis, M., Goff, D., et al., 2005. A summary of the FDA-NIMH MATRICS
Workshop on clinical trial design for neurocognitive drugs for schizophrenia.
Schizophr. Bull. 31, 5–19.
Davis, J.M., Chen, N., 2004. Dose response and dose equivalence of antipsychotics. J. Clin.
Psychopharmacol. 24, 192–208.
Enomoto, T., Ishibashi, T., Tokuda, K., et al., 2008. Lurasidone reverses MK-801-induced
impairment of learning and memory in the Morris water maze and radial-arm
maze tests in rats. Behav. Brain Res. 186, 197–207.
Fitzmaurice, G.M., Laird, N.M., Ware, J.H., 2004. Applied longitudinal analysis. John Wiley
& Sons, Inc., New Jersey.
Harvey, P.D., Keefe, R.S.E., 2001. Studies of cognitive change in patients with schizophre-
nia following novel antipsychotic treatment. Am. J. Psychiatry 158, 176–184.
Harvey, P.D., Siu, C.O., Romano, S., 2004. Randomized, controlled, double-blind, multicen-
ter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill
in patients with schizophrenia or schizoaffective disorder. Psychopharmacology 172,
324–332.
Harvey, P.D., Ogasa, M., Cucchiaro, J., et al., 2011. Performance and interview-based as-
sessments of cognitive change in a randomized, double-blind comparison of
lurasidone vs. ziprasidone. Schizophr. Res. 127, 188–194.
Harvey, P.D., Siu, C.O., Hsu, J., Cucchiaro, J., Maruff, P., Loebel, A., 2013. Effect of lurasidone
on neurocognitive performance in patients with schizophrenia: a short-term
placebo- and active-controlled study followed by a 6-month double-blind extension.
Eur. Neuropsychopharmacol. 23, 1373–1382.
Horisawa, T., Ishibashi, T., Nishikawa, H., et al., 2011. The effects of selective antagonists of
serotonin 5-HT7 and 5-HT1A receptors on MK-801-induced impairment of learning
andmemory in the passive avoidance andMorris watermaze tests in rats: mechanis-
tic implications for the beneﬁcial effects of the novel atypical antipsychotic
lurasidone. Behav. Brain Res. 220, 83–90.
Ishiyama, T., Tokuda, K., Ishibashi, T., et al., 2007. Lurasidone (SM-13496), a novel atypical
antipsychotic drug, reversesMK-801-induced impairment of learning andmemory in
the rat passive-avoidance test. Eur. J. Pharmacol. 572, 160–170.
Ishibashi, T., Horisawa, T., Tokuda, K., et al., 2010. Pharmacological proﬁle of lurasidone, a
novel antipsychotic agent with potent 5-HT7 and 5-HT1A receptor activity.
J. Pharmacol. Exp. Ther. 334, 171–181.
Keefe, R.S.E., Bilder, R.M., Davis, S.M., et al., 2007. Neurocognitive effects of antipsychotic
medications in patients with chronic schizophrenia in the CATIE trial. Arch. Gen. Psy-
chiatry 64, 633–647.
Keefe, R.S.E., Buchanan, R.W., Marder, S.R., et al., 2013. Clinical trials of potential cognitive
enhancing drugs in schizophrenia: what have we learned so far? Schizophr. Bull. 39,
417–435.
Leifker, F.R., Patterson, T.L., Heaton, R.K., et al., 2011. Validating measures of real world
outcome: the results of the VALERO expert survey and RAND panel. Schizophr. Bull.
37, 334–343.
Loebel, A., Cucchiaro, J., Sarma, K., et al., 2013a. Efﬁcacy and safety of lurasidone 80 mg/
day and 160 mg/day in the treatment of schizophrenia: a randomized, double-
blind, placebo- and active-controlled trial. Schizophr. Res. 145, 101–109.
Loebel, A., Cucchiaro, J., Xu, J., et al., 2013b. Effectiveness of lurasidone vs. quetiapine XR
for relapse prevention in schizophrenia: a 12-month, double-blind, continuation
study. Schizophr. Res. 147, 95–102.
Loebel, A., Siu, C.O., Cucchiaro, J., et al., 2013c. Daytime sleepiness associated with
lurasidone and quetiapine XR: a randomized, double-blind, placebo-controlled trial
in patients with schizophrenia. CNS Spectr. 19, 197–205.
Mausbach, B.T., Harvey, P.D., Goldman, S.R., et al., 2007. Development of a brief scale of
everyday functioning in persons with serious mental illness. Schizophr. Bull. 33,
1364–1372.
Nuechterlein, K.H., Subotnik, K.L., Ventura, J., Green, M.F., Gretchen-Doorly, D., Asamow,
R.F., 2012. The puzzle of schizophrenia: tracking the core role of cognitive deﬁcits.
Dev. Psychopathol. 24, 529–536.
Pietrzak, R.H., Olver, J., Norman, T., et al., 2009. A comparison of the CogState schizophre-
nia battery and the Measurement and Treatment Research to Improve Cognition in
Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic
schizophrenia. J. Clin. Exp. Neuropsychol. 31, 848–859.
Potkin, S.G., Weiden, P.J., Loebel, A.D., Warrington, L.E., Watsky, E.J., Siu, C.O., 2009. Remis-
sion in schizophrenia: 196-week double-blind treatment with ziprasidone versus
haloperidol. Int. J. Neuropsychopharmacol. 12, 1233–1248.
Stahl, S.M., Malla, A., Newcomer, J.W., et al., 2010. A post hoc analysis of negative symp-
toms and psychosocial function in patients with schizophrenia: a 40-week random-
ized, double-blind study of ziprasidone versus haloperidol followed by a 3-year
double-blind extension trial. J. Clin. Psychopharmacol. 12, 319–326.
Witek Jr., T.J., Canestrari, D.A., Miller, R.D., Yang, J.Y., Riker, D.K., 1995. Characterization of
daytime sleepiness and psychomotor performance following H1 receptor antago-
nists. Ann. Allergy Asthma Immunol. 74, 419–426.
